This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Merlini G, Palladini G. Differential diagnosis of monoclonal gammopathy of undetermined significance. Hematology Am Soc Hematol Educ Program. 2012;2012:595–603.
Wadhera RK, Rajkumar SV. Prevalence of monoclonal gammopathy of undetermined significance: a systematic review. Mayo Clin Proc. 2010;85:933–42.
Went M, Sud A, Forsti A, Halvarsson BM, Weinhold N, Kimber S, et al. Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma. Nat Commun. 2018;9:3707.
Thomsen H, Campo C, Weinhold N, Filho MI, Pour L, Gregora E, et al. Genome-wide association study on monoclonal gammopathy of unknown significance (MGUS). Eur J Haematol. 2017;99:70–9.
Weinhold N, Johnson DC, Rawstron AC, Forsti A, Doughty C, Vijayakrishnan J, et al. Inherited genetic susceptibility to monoclonal gammopathy of unknown significance. Blood. 2014;123:2513–7.
Chubb D, Weinhold N, Broderick P, Chen B, Johnson DC, Forsti A, et al. Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk. Nat Genet. 2013;45:1221–5.
Kazenwadel J, Betterman KL, Chong CE, Stokes PH, Lee YK, Secker GA, et al. GATA2 is required for lymphatic vessel valve development and maintenance. J Clin Invest. 2015;125:2979–94.
Golmard L, Castera L, Krieger S, Moncoutier V, Abidallah K, Tenreiro H, et al. Contribution of germline deleterious variants in the RAD51 paralogs to breast and ovarian cancers. Eur J Hum Genet. 2017;25:1345–53.
Bennett JA, Braga AC, Pinto A, Van de Vijver K, Cornejo K, Pesci A, et al. Uterine PEComas: a morphologic, immunohistochemical, and molecular analysis of 32 tumors. Am J Surg Pathol. 2018;42:1370–83.
Bjorklund CC, Ma W, Wang ZQ, Davis RE, Kuhn DJ, Kornblau SM, et al. Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide. J Biol Chem. 2011;286:11009–20.
Manni S, Carrino M, Manzoni M, Gianesin K, Nunes SC, Costacurta M, et al. Inactivation of CK1alpha in multiple myeloma empowers drug cytotoxicity by affecting AKT and beta-catenin survival signaling pathways. Oncotarget. 2017;8:14604–19.
Hu Y, Song W, Cirstea D, Lu D, Munshi NC, Anderson KC. CSNK1alpha1 mediates malignant plasma cell survival. Leukemia. 2015;29:474–82.
Lebovitz CB, Robertson AG, Goya R, Jones SJ, Morin RD, Marra MA, et al. Cross-cancer profiling of molecular alterations within the human autophagy interaction network. Autophagy. 2015;11:1668–87.
Hengeveld PJ, Kersten MJ. B-cell activating factor in the pathophysiology of multiple myeloma: a target for therapy? Blood Cancer J. 2015;5:e282.
Chattopadhyay S, Thomsen H, da Silva Filho MI, Weinhold N, Hoffmann P, Nothen MM, et al. Enrichment of B cell receptor signaling and epidermal growth factor receptor pathways in monoclonal gammopathy of undetermined significance: a genome-wide genetic interaction study. Mol Med. 2018;24:30.
Acknowledgements
Supported by Multiple Myeloma Research Foundation, the German Ministry of Education and Science (01ZX1309B), the Harald Huppert Foundation, and Deutsche Krebshilfe. Research by the Houlston Group is supported by grants from myeloma UK and BLOODWISE. PV and LV are recipients of a support from UNCE-MED006 and PROGRESS Q28.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Thomsen, H., Chattopadhyay, S., Weinhold, N. et al. Genome-wide association study of monoclonal gammopathy of unknown significance (MGUS): comparison with multiple myeloma. Leukemia 33, 1817–1821 (2019). https://doi.org/10.1038/s41375-019-0396-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41375-019-0396-x
This article is cited by
-
Identification of novel loci for multiple myeloma when comparing with its precursor condition monoclonal gammopathy of unknown significance
Leukemia (2023)
-
A genetic risk score of alleles related to MGUS interacts with socioeconomic position in a population-based cohort
Scientific Reports (2022)
-
Genome-wide meta-analysis of monoclonal gammopathy of undetermined significance (MGUS) identifies risk loci impacting IRF-6
Blood Cancer Journal (2022)
-
Incidence, mortality and survival in multiple myeloma compared to other hematopoietic neoplasms in Sweden up to year 2016
Scientific Reports (2021)
-
Genetic predisposition for multiple myeloma
Leukemia (2020)